Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Is Swartz Schedule 13G Due According To Rule 13d-1(c) NLT Feb 14?

What I find more interesting/suspicious: why have there been no 13G-filings in the years before, as Swartz had much more than 10% of PTSC?

 

To facilitate the conversion of the debentures, agreements between the Company and Lincoln and Swartz which prohibit each of Lincoln and Swartz from owning more than 4.99% of the Company's Common Stock will be amended to allow them to own up to 9.99% of the Common Stock. With their holdings exceeding 5% they will need to make appropriate SEC filings upon future dispositions of the Company's stock.

 

Prior to February 10, 2006, there was no need for them to file as they were below the 5% reporting threshold.

 

 

 

Be well

 

Share
New Message
Please login to post a reply